Table 1.
Characteristics of Cohort Patients Who Underwent Initial Surgery for Curative Treatment for PTC
| All (n = 54) | Tissue BRAFV600Epositive (n = 36) | Tissue BRAFwt(n = 18) | p-Value | |
|---|---|---|---|---|
| Demographics | ||||
| Female, n (%) | 38 (70) | 25 (69) | 13 (72) | 0.99 |
| Age at surgery, M (±SD) | 46.9 (15.1) | 44.8 (13.5) | 51.0 (17.5) | 0.16 |
| Primary tumor characteristics | ||||
| Tumor maximum diameter (mm), M (±SD) | 1.9 (1.3) | 1.9 (1.2) | 1.8 (1.3) | 0.92 |
| Extrathyroidal extension, n (%) | 19 (35) | 14 (39) | 5 (28) | 0.55 |
| Lymphovascular invasion, n (%) | 27 (51) | 21 (58) | 6 (35) | 0.15 |
| Cervical lymph node status, n (%) | ||||
| Central lymph node metastases | 23 (42.6) | 18 (50.0) | 5 (27.8) | 0.15 |
| Lateral lymph node metastases | 11 (20.4) | 8 (22.2) | 3 (16.7) | 0.73 |
| AJCC TNM stage, n (%) | 0.35 | |||
| I | 37 (69) | 25 (69) | 12 (67) | |
| II | 4 (7) | 1 (3) | 3 (7) | |
| III | 5 (9) | 4 (1) | 1 (6) | |
| IV | 8 (5) | 6 (7) | 2 (1) | |
| Blood BRAFV600Elevel | ||||
| Preoperative level (fg/ng RNA), median (IQR) | 301.5 (136.3–608.0) | 370.0 (203.3–686.5) | 136.5 (85.3–354.0) | 0.03 |
| Postoperative level (fg/ng RNA), median (IQR) | 177.5 (80.0–254.8) | 178.5 (75.8–305.5) | 158.0 (87.0–223.3) | 0.73 |
PTC, papillary thyroid carcinoma; wt, wild type; SD, standard deviation; AJCC TNM, American Joint Committee of Cancer Tumor, Node, Metastasis; IQR, interquartile range.